Original Article
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
N Engl J Med 2010; 363:24-35July 1, 2010
- Abstract
Background
Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown.
Methods
We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer.
Results
The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage.
Conclusions
Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)
Media in This Article
Figure 1
Kaplan–Meier Estimates of Survival among the Study Patients with Oropharyngeal Cancer, According to Tumor HPV Status or p16-Expression Status.Figure 2
Classification of the Study Patients into Risk-of-Death Categories and Kaplan–Meier Estimates of Overall Survival According to Those Categories.Article Activity
- Article
The majority of patients enrolled in therapeutic trials for squamous-cell carcinoma of the head and neck have oropharyngeal squamous-cell carcinoma, which in a subgroup of these patients is caused by infection with human papillomavirus (HPV).1 This subgroup is defined by the presence of high-risk types of HPV in tumor cells, predominantly HPV type 16 (HPV-16). Expression of viral E6 and E7 oncoproteins that inactivate the tumor-suppressor proteins p53 and the retinoblastoma protein (pRb), respectively, is necessary for malignant behavior of these tumors.2
Several retrospective case series have shown that among patients with oropharyngeal squamous-cell carcinoma, patients with HPV-positive tumors have a better prognosis than patients with HPV-negative tumors.3 Similar findings were reported in a prospective analysis of data from a clinical trial.4 Because of the small sample, however, other favorable prognostic factors associated with tumor HPV status (e.g., early tumor stage or young age) could not be ruled out as an explanation for the observed difference in survival.
We sought to evaluate the effect of tumor HPV status on survival in patients with oropharyngeal squamous-cell carcinoma who were enrolled in a clinical trial of sufficient size to account for potentially confounding factors, including smoking status. Our analysis was performed within a randomized clinical trial conducted by the Radiation Therapy Oncology Group (RTOG; the RTOG 0129 study). Meta-analyses of clinical trials for patients with locally advanced squamous-cell carcinoma of the head and neck have shown that both accelerated-fractionation radiotherapy5 and concurrent cisplatin-based chemotherapy improved survival as compared with standard-fractionation radiotherapy alone.6 The RTOG 0129 study addressed the question of whether accelerated-fractionation radiotherapy is superior to standard-fractionation radiotherapy when each radiotherapy regimen is combined with concurrent cisplatin therapy. We report the results of this trial with an emphasis on the effect of tumor HPV status on survival among patients with oropharyngeal squamous-cell carcinoma.
Methods
Study Protocol
The RTOG 0129 study was registered with the National Cancer Institute and approved by the institutional review boards at the participating centers. All patients provided written informed consent. The authors attest to the fidelity of the article to the full protocol and statistical-analysis plan.
Eligibility criteria were the presence of untreated, pathologically confirmed, stage III or IV squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx without distant metastases (M0)7; Zubrod's performance status score of 0 or 1 (asymptomatic or symptomatic but ambulatory, respectively)8; age of 18 years or older; and adequate bone marrow, hepatic, and renal function. Lifetime tobacco exposure was determined at enrollment with the use of a standardized, self-administered questionnaire.
Patients were stratified on the basis of the tumor site (larynx vs. other), nodal stage (N0 vs. N1, N2a, or N2b vs. N2c or N3), and Zubrod's performance status score (0 vs. 1) and were randomly assigned to receive high-dose cisplatin concurrently with either accelerated-fractionation radiotherapy (with the acceleration provided by means of concomitant boost radiotherapy) or standard-fractionation radiotherapy. The accelerated-fractionation radiotherapy consisted of the delivery of 72 Gy in 42 fractions over a 6-week period, with a concomitant boost of twice-daily irradiation for 12 treatment days (as previously reported9), and standard-fractionation radiotherapy consisted of the delivery of 70 Gy in 35 fractions (i.e., 2 Gy per fraction) over a 7-week period. Intravenous cisplatin was administered at a dose of 100 mg per square meter of body-surface area on days 1 and 22 in the accelerated-fractionation radiotherapy group and on days 1, 22, and 43 in the standard-fractionation radiotherapy group.
Acute toxicity was evaluated weekly during the period of therapy according to the Common Terminology Criteria, version 2.0 (http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf). To assess tumor status and late toxicity, according to RTOG criteria,10 physical examinations and imaging studies were performed every 3 months for the first 2 years, every 6 months during years 3 through 5, and annually thereafter.
Laboratory Studies
The analysis of tumor HPV status was restricted to patients with oropharyngeal squamous-cell carcinoma because of the low prevalence of HPV among nonoropharyngeal squamous-cell carcinomas.1 This post hoc subgroup analysis was not part of the study protocol. Formalin-fixed, paraffin-embedded tumor specimens were evaluated for HPV-16 DNA with the use of the in situ hybridization–catalyzed signal-amplification method for biotinylated probes (GenPoint, Dako).11 HPV-16–negative tumors were further evaluated for 12 additional oncogenic HPV types (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) by means of a biotinylated-probe cocktail (GenPoint HPV Probe Cocktail, Dako). An HPV-positive tumor was defined as a tumor for which there was specific staining of tumor-cell nuclei for HPV in either analysis.
Tumor p16 expression was evaluated by means of immunohistochemical analysis with a mouse monoclonal antibody (MTM Laboratories) visualized with use of an autostainer (Ventana XT, Ventana) and a one-view secondary detection kit (Ventana).12 Positive p16 expression was defined as strong and diffuse nuclear and cytoplasmic staining in 70% or more of the tumor cells.12
Study End Points
The primary end point was overall survival, defined as the time from randomization to death. Secondary end points included progression-free survival, defined as the time from randomization to death or the first documented relapse, which was categorized as local–regional disease (tumor at the primary site or regional nodes) or distant metastases. Death from the primary cancer without a documented site of recurrence or death from an unknown cause was considered death from local–regional disease. Second primary tumors were evaluated separately. Progression-free survival and its components (local–regional disease and distant metastases) were reported instead of protocol-specified secondary end points (e.g., disease-free survival) to facilitate comparison with published meta-analyses.13
Statistical Analysis
With a sample of 720 patients, the RTOG 0129 study had 80% statistical power to detect a relative reduction of 25% in the rate of death in the accelerated-fractionation radiotherapy group as compared with the standard-fractionation radiotherapy group, assuming a 2-year rate of overall survival of 45% in the standard-fractionation radiotherapy group,14,15 with the use of a one-sided test at the 0.05 significance level.
Rates of overall survival and progression-free survival were estimated by means of the Kaplan–Meier method and were compared between the two groups with the use of the log-rank test. The cumulative incidence method and Gray's test were used to estimate and compare rates of local–regional relapse, distant metastases, and second primary tumors.
Cox proportional-hazards models were used to estimate hazard ratios; multivariable models were developed by minimizing Akaike's information criterion. Cox regression was performed with the use of data on tumor HPV status and smoking status, for patients for whom these data were available. Unadjusted and adjusted hazard ratios for HPV-positive and HPV-negative status were compared between the two groups to estimate the proportion of the difference in survival that was attributable to covariates. To investigate potential bias in estimates due to missing data on HPV status, we repeated the analyses for the subgroup of patients with oropharyngeal squamous-cell carcinoma and for the entire RTOG study cohort (assuming the nonoropharyngeal squamous-cell carcinoma tumors were HPV-negative), using values imputed with the Markov chain Monte Carlo algorithm with a noninformative prior distribution (SAS/STAT software, with SAS OnlineDoc 9.1.3; SAS Institute). Twenty data sets were created, and the resulting analyses were combined per Rubin's formula.16 Recursive-partitioning analysis (for censored survival data) was performed with the use of S-Tree software (http://peace.med.yale.edu/pub/stree) to identify the factors that were most influential for overall survival and to permit the classification of patients with oropharyngeal squamous-cell carcinoma as having a low, intermediate, or high risk of death.17
Results
Characteristics of the Patients
From July 2002 through May 2005, a total of 743 patients were enrolled in the RTOG 0129 study and randomly assigned to receive accelerated-fractionation radiotherapy or standard-fractionation radiotherapy. Analyses were restricted to the 721 patients who met the protocol study criteria (360 patients in the accelerated-fractionation radiotherapy group and the 361 patients in the standard-fractionation radiotherapy group); of the remaining 22 patients, 17 were found to be ineligible and 5 withdrew consent. The baseline characteristics of the two groups are listed in Table 1Table 1
Baseline Characteristics of the Study Patients and Their Tumors, According to Patient Group..The majority of enrolled patients (60.1% [433 of 721]) had oropharyngeal squamous-cell carcinoma, and HPV status was determined in 74.6% of these patients (323 of 433). Tumor specimens were not available for study in 94 patients, and tissue specimens from 16 patients did not contain tumor tissue. No significant differences in baseline characteristics, overall survival, or progression-free survival were found between patients in whom HPV status was determined and those in whom it was not, arguing against significant selection bias (see the Supplementary Appendix, available with the full text of this article at NEJM.org). HPV DNA was detected in 63.8% of patients' tumors (206 of the 323) by means of in situ hybridization, and 96.1% of the samples (198 of 206) were positive for HPV-16.
HPV-positive oropharyngeal cancer was more common among patients who had never smoked and those with a lower number of cumulative pack-years of tobacco smoking than among those with a history of heavier smoking and was also significantly associated with several favorable prognostic factors, including younger age, white race, better performance status, absence of anemia, and smaller primary tumors (Table 1). The two treatment groups were balanced with regard to tumor HPV status.
Survival and Toxicity
There were no significant differences between the accelerated-fractionation radiotherapy group and the standard-fractionation radiotherapy group with regard to the rate of death within 30 days after the start of therapy (3.3% and 1.9%, respectively; P=0.26) or the overall rates of grade 3 or 4 acute toxic events (80.0% and 83.7%, respectively; P=0.21) and late toxic events (25.7% and 21.1%, respectively; P=0.18). At the data cutoff point (August 2009), 418 patients were alive. After a median follow-up of 4.8 years (range, 0.3 to 6.5), there was no significant difference in the 3-year rate of overall survival between the accelerated-fractionation radiotherapy group (70.3%; 95% confidence interval [CI], 65.6 to 75.1) and the standard-fractionation radiotherapy group (64.3%; 95% CI, 59.3 to 69.2; P=0.18). There was a nonsignificant reduction of 10% in the risk of death for the accelerated-fractionation radiotherapy group as compared with the standard-fractionation radiotherapy group (hazard ratio, 0.90; 95% CI, 0.72 to 1.13), with a similar reduction in the subgroup of patients with HPV-positive cancer (11%; hazard ratio, 0.89; 95% CI, 0.51 to 1.55) and in the subgroup with HPV-negative cancer (9%; hazard ratio, 0.91; 95% CI, 0.69 to 1.19). The accelerated-fractionation radiotherapy group and the standard-fractionation radiotherapy group did not differ significantly with regard to progression-free survival or the pattern of relapse (see the Supplementary Appendix).
HPV Status and Survival
For analysis of the association of tumor HPV status with survival, we combined the data for all patients with oropharyngeal squamous-cell carcinoma, since the survival rates were similar in the two treatment groups. In a Kaplan–Meier analysis, patients with HPV-positive cancer had better overall survival and progression-free survival than patients with HPV-negative cancer (P<0.001 for both end points, by the log-rank test). The 3-year rates of overall survival were 82.4% (95% CI, 77.2 to 87.6) in the HPV-positive subgroup and 57.1% (95% CI, 48.1 to 66.1) in the HPV-negative subgroup (Figure 1AFigure 1
Kaplan–Meier Estimates of Survival among the Study Patients with Oropharyngeal Cancer, According to Tumor HPV Status or p16-Expression Status.), and the 3-year rates of progression-free survival were 73.7% (95% CI, 67.7 to 79.8) and 43.4% (95% CI, 34.4 to 52.4), respectively (Figure 1B).In the multivariable analysis, age, race, performance status, tumor stage, nodal stage, and number of pack-years of tobacco smoking were also significant determinants of overall survival and progression-free survival (Table 2Table 2
Hazard Ratios for Overall and Progression-free Survival, According to Patient Group.). By comparing the unadjusted hazard ratios for HPV-positive versus HPV-negative tumor status (hazard ratio for death, 0.38; 95% CI, 0.26 to 0.55; and hazard ratio for relapse or death, 0.40; 95% CI, 0.29 to 0.57) (Figure 1A and 1B) with the corresponding adjusted hazard ratios (provided below), we estimated that these factors accounted for a relative difference of approximately 9% in the rates of overall survival and progression-free survival between patients with HPV-positive and those with HPV-negative oropharyngeal squamous-cell carcinoma. Nonetheless, after this adjustment, patients with HPV-positive tumors had a 58% reduction in the risk of death as compared with patients with HPV-negative tumors (hazard ratio, 0.42; 95% CI, 0.27 to 0.66) and a 51% reduction in the risk of relapse or death (hazard ratio, 0.49; 95% CI, 0.33 to 0.74) (Table 2). After imputation for missing data, the results were similar (Table 2).Tumors were evaluated for the expression of not only HPV but also a known biomarker of HPV-oncoprotein function, the cyclin-dependent–kinase inhibitor p16, which is induced as a consequence of pRb inactivation by the HPV E7 oncoprotein18 but is minimally detectable in HPV-negative tumors because of epigenetic or genetic silencing.19 The presence of HPV DNA and the presence of p16 expression in tumors had very good agreement (kappa=0.80; 95% CI, 0.73 to 0.87). Using p16 expression as a stratification factor, we found differences in overall and progression-free survival that were consistent with those based on HPV status. In unadjusted analyses, the 3-year rate of overall survival was 83.6% (95% CI, 78.7 to 88.6) in the subgroup that was positive for p16 expression and 51.3% (95% CI, 41.5 to 61.0) in the subgroup that was negative for p16 expression (hazard ratio for death with positive p16 expression, 0.29; 95% CI, 0.20 to 0.43) (Figure 1C); the 3-year rate of progression-free survival was 74.4% (95% CI, 68.5 to 80.2) and 38.4% (95% CI, 28.9 to 47.9), respectively (hazard ratio for relapse or death with positive p16 expression, 0.33; 95% CI, 0.24 to 0.46) (Figure 1D). After adjustment for other factors, the corresponding hazard ratio for death was 0.33 (95% CI, 0.21 to 0.53), and the corresponding hazard ratio for relapse or death was 0.42 (95% CI, 0.28 to 0.64).
Tobacco smoking was also independently associated with overall survival and progression-free survival both in the subgroup of patients with oropharyngeal squamous-cell carcinoma and in the entire study population (Table 2). The risks of death and cancer relapse or death significantly increased by 1% for each additional pack-year of tobacco smoking (Table 2), and the magnitude of the tobacco effect was similar for patients with HPV-positive cancer (hazard ratio, 1.01; 95% CI, 1.00 to 1.02) and those with HPV-negative cancer (hazard ratio, 1.01; 95% CI, 1.00 to 1.03).
In an analysis of patterns of treatment failure among patients with oropharyngeal squamous-cell carcinoma, the 3-year rate of local–regional disease, but not distant metastasis, was significantly lower for patients with HPV-positive tumors than for those with HPV-negative tumors (13.6% vs. 35.1%, P<0.001) (Table 3Table 3
Survival Estimates, Causes of Death, and Patterns of Treatment Failure in Patients with Oropharyngeal Cancer, According to Tumor HPV Status.). In addition, the cumulative incidence of second primary tumors was significantly lower among patients with HPV-positive tumors, largely because of lower rates of smoking-related cancer (Table 3).Recursive-partitioning analysis showed that the HPV status of the tumor was the major determinant of overall survival, followed by the number of pack-years of tobacco smoking (≤10 vs. >10) and then nodal stage (N0 to N2a vs. N2b to N3), for HPV-positive tumors, or tumor stage (T2 or T3 vs. T4), for HPV-negative tumors (Figure 2AFigure 2
Classification of the Study Patients into Risk-of-Death Categories and Kaplan–Meier Estimates of Overall Survival According to Those Categories.). This analysis classified patients with oropharyngeal squamous-cell carcinoma into three categories with respect to the risk of death: low risk, with a 3-year rate of overall survival of 93.0%; intermediate risk, with a 3-year rate of 70.8% (hazard ratio for the comparison with low risk, 3.54; 95% CI, 1.91 to 6.57); and high risk, with a 3-year rate of 46.2% (hazard ratio for the comparison with low risk, 7.16; 95% CI, 3.97 to 12.93) (Figure 2B). Patients with HPV-positive tumors were considered to be at low risk, with the exception of smokers with a high nodal stage (i.e., N2b to N3), who were considered to be at intermediate risk; patients with HPV-negative tumors were considered to be at high risk, with the exception of nonsmokers with tumors of stage T2 or T3, who were considered to be at intermediate risk.Discussion
This study provides strong evidence that tumor HPV status is an independent prognostic factor for overall survival and progression-free survival among patients with oropharyngeal squamous-cell carcinomas, which is consistent with the hypothesis that HPV-positive and HPV-negative oropharyngeal squamous-cell carcinomas are distinct and have different causes,20 risk-factor profiles,1 and survival outcomes. On the basis of our data, we believe that future clinical trials should be designed specifically for patients with HPV-positive or HPV-negative squamous-cell carcinoma of the head and neck or patients who have been stratified according to HPV status. Moreover, additional information could be gleaned from completed clinical trials, by means of reanalysis, to determine whether imbalances in tumor HPV status between treatment groups affected the outcomes and thus the therapeutic implications.
Our analysis of the association of HPV status with survival was performed in a clinical trial of locally advanced squamous-cell carcinoma of the head and neck that did not show a significant difference in overall survival between a concomitant-boost accelerated-fractionation regimen of radiotherapy and a standard-fractionation regimen, combined with concurrent, high-dose cisplatin. Therefore, either regimen could serve as the comparison for a new therapy being investigated.
We observed strong agreement between tumor HPV status, as determined by in situ hybridization, and expression of p16, an established biomarker for the function of the HPV E7 oncoprotein. Our HPV-16 in situ hybridization assay has sensitivity for single viral copies, and a positive result is strongly correlated with expression of the HPV E6 and E7 oncogenes — the standard for defining a tumor as being associated with HPV.21,22 A limitation of our method is the unknown sensitivity of the probe cocktail for non–HPV-16 types, which account for an estimated 5 to 10% of HPV-positive oropharyngeal squamous-cell carcinomas.23 Thus, the misclassification of HPV-positive tumors as HPV-negative tumors probably explains the slightly larger reduction in the risk of death when the analysis was based on status with respect to p16 expression rather than HPV presence. A strength of the p16-expression assay is that it is not specific for HPV type, unlike the in situ hybridization assays; therefore, p16-expression status is a very good surrogate for tumor HPV status.
The superior prognosis for HPV-positive oropharyngeal squamous-cell carcinoma, as compared with that for the HPV-negative cancer, appears to have multifactorial underpinnings. Known favorable prognostic factors associated with the HPV-positive subgroup account for approximately 10% of the detected difference in outcome. The higher survival rate among patients with HPV-positive cancer is due in part to greater local–regional control, reflecting higher intrinsic sensitivity to radiation or better radiosensitization with the use of cisplatin. Although rates of response to induction chemotherapy are higher among patients with HPV-positive tumors than among those with HPV-negative tumors,4 single-agent cisplatin therapy did not appear to differentially affect the elimination of occult distant metastases. Second primary tumors, which are largely related to smoking, were less frequent among patients with HPV-positive tumors, a finding that is consistent with the lower exposure to tobacco in this subgroup. However, the rates of death from second primary tumors were similar in the HPV-positive and HPV-negative subgroups and therefore do not account for the overall differences in survival rates.
Our data clearly indicate that HPV status and status with respect to tobacco smoking are major independent prognostic factors for patients with oropharyngeal squamous-cell carcinoma, probably because they determine the molecular profile of the cancer and thus the response to therapy. Although HPV-positive oropharyngeal squamous-cell carcinoma is genetically distinct from the HPV-negative cancer with respect to patterns of loss of heterozygosity,24 chromosomal abnormalities,25,26 and gene-expression profiles27 and is inversely correlated with biomarkers for a poor prognosis in squamous-cell carcinoma of the head and neck (e.g., p53 mutations28 or expression of epidermal growth factor receptor29), no specific mechanism has been shown to explain the higher rates of response to radiation therapy and chemotherapy among patients with HPV-positive cancer.4 Epidemiologic data indicate that tobacco smoking is not a strong cofactor for the development of HPV-positive oropharyngeal squamous-cell carcinoma.1 Nevertheless, our data reveal that the biologic behavior of an HPV-positive tumor may be altered by tobacco use. Genetic alterations induced by tobacco-associated carcinogens may render HPV-positive tumors less responsive to therapy. The likelihood of such genetic alterations appears to increase as the number of pack-years of tobacco smoking increases (Table 2). The cutoff point of 10 pack-years, which was the best predictor of survival in our recursive-partitioning analysis, may be more useful than a continuum for the design of future risk-based clinical trials but will require further validation.
The extent to which the superior survival for a patient with HPV-positive oropharyngeal squamous-cell carcinoma depends on the administered therapy is unclear. Published data indicate that tumor HPV status is a strong and consistent determinant of superior survival, regardless of treatment strategy (e.g., surgery,30 radiation therapy,31,32 concurrent chemoradiation therapy [in this study], or induction chemotherapy plus concurrent chemoradiation therapy4,33), with 5-year survival rates among patients with HPV-positive tumors of approximately 75 to 80%, versus 45 to 50% among patients with HPV-negative tumors.
Though no direct evidence from formal clinical trials exists to guide treatment decisions for the individual patient on the basis of tumor HPV status, this study provides a direction for future clinical research. A combination of tumor HPV status, pack-years of tobacco smoking, and cancer stage may be used to classify patients as having a low, intermediate, or high risk of death. Whether patients with HPV-positive tumors who are considered to be in the low-risk category can be spared the long-term complications of intensive, multimodal therapy without compromising their survival is now a highly relevant clinical question. In contrast, such a strategy would be inappropriate for the 36% of patients with HPV-positive tumors who are in the intermediate-risk group, for whom the 3-year rate of overall survival (71%, with an even lower rate of progression-free survival) is unacceptable. Unfortunately, patients in the high-risk group have an extremely poor prognosis and thus should be offered enrollment in trials testing more intensive investigational therapies. Should our risk model be validated in other cohorts, it will be important to incorporate tumor HPV status and tobacco exposure as nonanatomical determinants of risk classification and therapy selection for patients with oropharyngeal squamous-cell carcinoma.
The contents of this article are the sole responsibility of the authors and do not necessarily represent the official views of the NCI or NIDCR.
Supported by grants (RTOG U10 CA21661, CCOP U10 CA37422, and P01 CA06294) from the National Cancer Institute (NCI), a grant (DE016631) from the National Institute of Dental and Craniofacial Research (NIDCR), and the Oral Cancer Foundation.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
This article (10.1056/NEJMoa0912217) was published on June 7, 2010, at NEJM.org.
Source Information
From the University of Texas M.D. Anderson Cancer Center, Houston (K.K.A., R. Weber, D.I.R., C.L.); Radiation Therapy Oncology Group Statistical Center (J.H.) and Thomas Jefferson University Hospital (R.A.) — both in Philadelphia; Huntsman Cancer Institute, Salt Lake City (R. Wheeler); Centre Hospitalier de l'Université de Montréal, Montreal (P.F.N.-T.); Johns Hopkins University, Baltimore (W.H.W.); Vanderbilt University School of Medicine, Nashville (C.H.C.); University of Louisville, Louisville, KY (C.C.S.); University of California at San Francisco, San Francisco (R.C.J.); Wayne State University Medical Center, Detroit (H.K.); University of Cincinnati College of Medicine, Cincinnati (K.P.R.); and the Ohio State University Comprehensive Cancer Center, Columbus (M.L.G.).
Address reprint requests to Dr. Gillison at Ohio State University, 420 W. 12th Ave., Rm. 690, Columbus, OH 43210, or at maura.gillison@osumc.edu.
- References
References
1
Gillison M ,D'Souza G ,Westra W , et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-420
CrossRef | Web of Science | Medline2
Rampias T ,Sasaki C ,Weinberger P ,Psyrri A . E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009;101:412-423
CrossRef | Web of Science | Medline3
Ragin CC ,Taioli E . Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121:1813-1820
CrossRef | Web of Science | Medline4
Fakhry C ,Westra WH ,Li S , et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269
CrossRef | Web of Science | Medline5
Bourhis J ,Overgaard J ,Audry H , et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-854
CrossRef | Web of Science | Medline6
Pignon J-P ,le Maitre A ,Maillard E ,Bourhis J . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14
CrossRef | Web of Science | Medline7
Fleming I, Cooper J, Henson D, et al., eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
8
Oken MM ,Creech RH ,Tormey DC , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655
CrossRef | Web of Science | Medline9
Fu KK ,Pajak TF ,Trotti A , et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16
CrossRef | Web of Science | Medline10
Cox JD ,Stetz J ,Pajak TF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346
CrossRef | Web of Science | Medline11
Huang CC ,Qiu JT ,Kashima ML ,Kurman RJ ,Wu TC . Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol 1998;11:971-977
Web of Science | Medline12
Begum S ,Gillison ML ,Ansari-Lari MA ,Shah K ,Westra WH . Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 2003;9:6469-6475
Web of Science | Medline13
Michiels S ,Le Maitre A ,Buyse M , et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 2009;10:341-350
CrossRef | Web of Science | Medline14
Marcial VA ,Pajak TF ,Mohiuddin M , et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck: long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer 1990;66:1861-1868
CrossRef | Web of Science | Medline15
Adelstein DJ ,Li Y ,Adams GL , et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98
CrossRef | Web of Science | Medline16
Rubin D, ed. Multiple imputations for nonresponse in surveys. New York: Wiley, 1987.
17
Analysis of censored data: survival trees. In: Zhang H, Singer B. Recursive partitioning in the health sciences. New York: Springer-Verlag, 1999:93-104.
18
Nakao Y ,Yang X ,Yokoyama M , et al. Induction of p16 during immortalization by HPV16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410-1416
CrossRef | Web of Science | Medline19
Reed AL ,Califano J ,Cairns P , et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3633
Web of Science | Medline20
Gillison ML ,Koch WM ,Capone RB , et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720
CrossRef | Web of Science | Medline21
Shi W ,Kato H ,Perez-Ordonez B , et al. Comparative prognostic value of HPV16 E6 mRNA compared with in-situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009;27:6213-6221
CrossRef | Web of Science | Medline22
Smeets SJ ,Hesselink AT ,Speel EJ , et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465-2472
CrossRef | Web of Science | Medline23
Kreimer AR ,Clifford GM ,Boyle P ,Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475
CrossRef | Web of Science | Medline24
Braakhuis BJ ,Snijders PJ ,Keune WJ , et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004;96:998-1006
CrossRef | Web of Science | Medline25
Klussman J ,Mooren J ,Lehnen M , et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 2009;15:1779-1786
CrossRef | Web of Science | Medline26
Smeets SJ ,Braakhuis BJ ,Abbas S , et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558-2564
CrossRef | Web of Science | Medline27
Martinez I ,Wang J ,Hobson KF ,Ferris RL ,Khan SA . Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007;43:415-432
CrossRef | Web of Science | Medline28
Westra WH ,Taube JM ,Poeta ML ,Begum S ,Sidransky D ,Koch WM . Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008;14:366-369
CrossRef | Web of Science | Medline29
Kumar B ,Cordell KG ,Lee JS , et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-3137
CrossRef | Web of Science | Medline30
Licitra L ,Perrone F ,Bossi P , et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630-5636
CrossRef | Web of Science | Medline31
Lindquist D ,Romanitan M ,Hammarstedt L , et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 2007;1:350-355
CrossRef | Medline32
Lassen P ,Eriksen JG ,Hamilton-Dutoit S ,Tramm T ,Alsner J ,Overgaard J . Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992-1998
CrossRef | Web of Science | Medline33
Settle K ,Posner MR ,Schumaker LM , et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila Pa) 2009;2:776-781
CrossRef | Web of Science
- Citing Articles (153)
Citing Articles
1
Camilla Molich Hoff. (2012) Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncologica1-14
CrossRef2
John R. Almeida, Eric M. Genden. (2012) Robotic Surgery for Oropharynx Cancer: Promise, Challenges, and Future Directions. Current Oncology Reports
CrossRef3
Jaana Rautava, Jonna Kuuskoski, Kari Syrjänen, Reidar Grenman, Stina Syrjänen. (2012) HPV genotypes and their prognostic significance in head and neck squamous cell carcinomas. Journal of Clinical Virology 53:2, 116-120
CrossRef4
Santanu Dasgupta, Rupesh Dash, Swadesh K. Das, Devanand Sarkar, Paul B. Fisher. (2012) Emerging strategies for the early detection and prevention of head and neck squamous cell cancer. Journal of Cellular Physiology 227:2, 467-473
CrossRef5
S. Guihard, A.-C. Jung, G. Noël. (2012) Carcinomes épidermoïdes oropharyngés liés à l’infection par les papillomavirus humains de haut risque oncogénique : aspects cliniques, biologiques et perspectives thérapeutiques. Cancer/Radiothérapie
CrossRef6
Julie K. Schwarz, James S. Lewis, John Pfeifer, Phyllis Huettner, Perry Grigsby. (2012) Prognostic Significance of p16 Expression in Advanced Cervical Cancer Treated with Definitive Radiotherapy. International Journal of Radiation Oncology*Biology*Physics
CrossRef7
Sean M. McBride, Nawal N. Ali, Danielle N. Margalit, Annie W. Chan. (2012) Active Tobacco Smoking and Distant Metastasis in Patients with Oropharyngeal Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef8
Katharine A. R. Price, Ezra E. Cohen. (2012) Current Treatment Options for Metastatic Head and Neck Cancer. Current Treatment Options in Oncology
CrossRef9
Christopher Schutt, Klaus Bumm, Leonardo Mirandola, Giovanni Bernardini, Nicholas D’ Cunha, Lukman Tijani, Diane Nguyen, Joehassin Cordero, Marjorie R. Jenkins, Everardo Cobos, W. Martin Kast, Maurizio Chiriva-Internati. (2012) Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. International Reviews of Immunology 31:1, 22-42
CrossRef10
E Junor, G Kerr, A Oniscu, S Campbell, I Kouzeli, C Gourley, K Cuschieri. (2012) Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. British Journal of Cancer 106:2, 358-365
CrossRef11
Brian Kim, Robert O. Dillman, Peter Chen, Russell Hafer, Craig Cox, Neil Barth, R. Matthew Carroll, Louis VanderMolen, Minh Nguyen, JinChu Huang, Annamarie Minion, Marianne Plunkett, Ralph Mackintosh. (2012) A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. American Journal of Otolaryngology 33:1, 93-97
CrossRef12
Clint T. Allen, Nancy P. Judd, Jack D. Bui, Ravindra Uppaluri. (2012) The clinical implications of antitumor immunity in head and neck cancer. The Laryngoscope 122:1, 144-157
CrossRef13
Xiaohong Iris Wang, Jaiyeola Thomas, Songlin Zhang. (2012) Changing trends in human papillomavirus–associated head and neck squamous cell carcinoma. Annals of Diagnostic Pathology 16:1, 7-12
CrossRef14
Guo-Pei Yu, Vikas Mehta, Daniel Branovan, Qiang Huang, Mia Hashibe, Zuo-Feng Zhang, Stimson P. Schantz. (2012) Improved survival among patients with base of tongue and tonsil cancer in the United States. Cancer Causes & Control 23:1, 153-164
CrossRef15
Caroline Conway, Rebecca Chalkley, Alec High, Kenneth Maclennan, Stefano Berri, Preetha Chengot, Melissa Alsop, Philip Egan, Joanne Morgan, Graham R. Taylor, John Chester, Mehmet Sen, Pamela Rabbitts, Henry M. Wood. (2012) Next-Generation Sequencing for Simultaneous Determination of HPV Load, Subtype, and Associated Genomic Copy Number Changes in Tumors. The Journal of Molecular Diagnostics
CrossRef16
Matthew E. Spector, K. Kelly Gallagher, Emily Light, Mohannad Ibrahim, Eric J. Chanowski, Jeffrey S. Moyer, Mark E. Prince, Gregory T. Wolf, Carol R. Bradford, Kitrina Cordell, Jonathan B. McHugh, Thomas Carey, Francis P. Worden, Avraham Eisbruch, Douglas B. Chepeha, . (2012) Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head & Neckn/a-n/a
CrossRef17
Shao Hui Huang, Bayardo Perez-Ordonez, Fei-Fei Liu, John Waldron, Jolie Ringash, Jonathan Irish, Bernard Cummings, Lillian L. Siu, John Kim, Ilan Weinreb, Andrew Hope, Patrick Gullane, Dale Brown, Willa Shi, Brian O’Sullivan. (2012) Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 82:1, 276-283
CrossRef18
Derrick Wansom, Emily Light, Dafydd Thomas, Francis Worden, Mark Prince, Susan Urba, Douglas Chepeha, Bhavna Kumar, Kitrina Cordell, Avraham Eisbruch, Jeremy Taylor, Jeffrey Moyer, Carol Bradford, Nisha D'Silva, Thomas Carey, Jonathan McHugh, Gregory Wolf, . (2012) Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. The Laryngoscope 122:1, 121-127
CrossRef19
Jason D. Howard, Bo Lu, Christine H. Chung. (2012) Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation. Oral Oncology 48:1, 10-17
CrossRef20
Christine G. Gourin, Kevin D. Frick. (2012) National trends in oropharyngeal cancer surgery and the effect of surgeon and hospital volume on short-term outcomes and cost of care. The Laryngoscopen/a-n/a
CrossRef21
J. Thariat, Y. Pointreau, R. -J. Bensadoun. (2012) 10e biennale monégasque de cancérologie : nouveautés ORL. Oncologie 14:1, 24-27
CrossRef22
Justin A. Bishop, Takenori Ogawa, Xiaofei Chang, Peter B. Illei, Edward Gabrielson, Sara I. Pai, William H. Westra. (2012) HPV Analysis in Distinguishing Second Primary Tumors From Lung Metastases in Patients With Head and Neck Squamous Cell Carcinoma. The American Journal of Surgical Pathology 36:1, 142-148
CrossRef23
Hisham Mehanna, Tom Beech, Tom Nicholson, Iman El-Hariry, Christopher McConkey, Vinidh Paleri, Sally Roberts, David W. Eisele. (2012) Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head & Neckn/a-n/a
CrossRef24
Giuseppe Sanguineti, Francesco Ricchetti, Binbin Wu, Nishant Agrawal, Christine Gourin, Harold Agbahiwe, Shanthi Marur, Stefania Clemente, Todd McNutt, Arlene Forastiere. (2012) Volumetric change of human papillomavirus-related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy. Head & Neckn/a-n/a
CrossRef25
Corey J. Langer. (2012) Exploring biomarkers in head and neck cancer. Cancern/a-n/a
CrossRef26
Alexandra V. Lucs, Benjamin Saltman, Christine H. Chung, Bettie M. Steinberg, David L. Schwartz, Jeffrey N. Myers. (2012) Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head & Neckn/a-n/a
CrossRef27
Chad Tang, James D. Murphy, Brian Khong, Trang H. La, Christina Kong, Nancy J. Fischbein, A. Dimitrios Colevas, Andrei H. Iagaru, Edward E. Graves, Billy W. Loo, Quynh-Thu Le. (2012) Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef28
Missak Haigentz, June Corry, Primoz Strojan, Alfio Ferlito. (2012) Easing acceleration of head and neck chemoradiotherapy. The Lancet Oncology
CrossRef29
Jean Bourhis, Christian Sire, Pierre Graff, Vincent Grégoire, Philippe Maingon, Gilles Calais, Bernard Gery, Laurent Martin, Marc Alfonsi, Patrick Desprez, Thierry Pignon, Etienne Bardet, Michel Rives, Lionel Geoffrois, Nicolas Daly-Schveitzer, Sok Sen, Claude Tuchais, Olivier Dupuis, Stéphane Guerif, Michel Lapeyre, Véronique Favrel, Marc Hamoir, Antoine Lusinchi, Stéphane Temam, Antonella Pinna, Yun Gan Tao, Pierre Blanchard, Anne Aupérin. (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. The Lancet Oncology
CrossRef30
Thomas J. Galloway, Miriam N. Lango, Barbara Burtness, Ranee Mehra, Karen Ruth, John A. Ridge. (2012) Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. Head & Neckn/a-n/a
CrossRef31
Peter A. Paximadis, Michael E. Christensen, Greg Dyson, Dev P. Kamdar, Ammar Sukari, Ho-Sheng Lin, George H. Yoo, Harold E. Kim. (2012) Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer. Head & Neckn/a-n/a
CrossRef32
Sven Gunia, Andreas Erbersdobler, Oliver W. Hakenberg, Stefan Koch, Matthias May. (2012) p16INK4a is a Marker of Good Prognosis for Primary Invasive Penile Squamous Cell Carcinoma: A Multi-Institutional Study. The Journal of Urology
CrossRef33
Victoria L. Green, Anna Michno, John Greenman, Nicholas D. Stafford. (2012) Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients. Results in Immunology 2, 1-6
CrossRef34
Markus Brunner, Oskar Koperek, Fritz Wrba, Boban M. Erovic, Gregor Heiduschka, Christian Schoppper, Dietmar Thurnher. (2011) HPV infection and p16 expression in carcinomas of the minor salivary glands. European Archives of Oto-Rhino-Laryngology
CrossRef35
Changqing Ma, James Lewis. (2011) Small Biopsy Specimens Reliably Indicate p16 Expression Status of Oropharyngeal Squamous Cell Carcinoma. Head and Neck Pathology
CrossRef36
Justin A. Bishop, James J. Sciubba, William H. Westra. (2011) Squamous Cell Carcinoma of the Oral Cavity and Oropharynx. Surgical Pathology Clinics 4:4, 1127-1151
CrossRef37
Jaiyeola Thomas, Thad Primeaux. (2011) Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus–associated head and neck squamous cell carcinoma?. Annals of Diagnostic Pathology
CrossRef38
Ranee Mehra, Ilya G. Serebriiskii, Roland L. Dunbrack, Matthew K. Robinson, Barbara Burtness, Erica A. Golemis. (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 14:6, 260-279
CrossRef39
David J. Sher, Marshall R. Posner, Roy B. Tishler, Nicholas J. Sarlis, Robert I. Haddad, Edward J. Holupka, Phillip M. Devlin. (2011) Relationship Between Radiation Treatment Time and Overall Survival After Induction Chemotherapy for Locally Advanced Head-and-Neck Carcinoma: A Subset Analysis of TAX 324. International Journal of Radiation Oncology*Biology*Physics 81:5, e813-e818
CrossRef40
Adrian R. Levy, Karissa M. Johnston, Jennifer Sambrook, Bonnie Donato, John R. Penrod, Mitra Corral, Martin Chasen. (2011) Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Current Medical Research and Opinion 27:12, 2253-2259
CrossRef41
Bruce H. Haughey, Michael L. Hinni, John R. Salassa, Richard E. Hayden, David G. Grant, Jason T. Rich, Simon Milov, James S. Lewis, Murli Krishna. (2011) Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A united states multicenter study. Head & Neck 33:12, 1683-1694
CrossRef42
Shang-Wen Chen, Shih-Neng Yang, Ji-An Liang. (2011) In Reply to Dr. Huang et al.. International Journal of Radiation Oncology*Biology*Physics 81:5, 1592
CrossRef43
Wen-Yen Huang, Yu-Fu Su, Kuen-Tze Lin, Jang-Chun Lin, Yao-Wen Chang, Chao-Yueh Fan. (2011) In Response to Dr. Yang and Colleagues. International Journal of Radiation Oncology*Biology*Physics 81:5, 1592
CrossRef44
Hui-Ching Chuang, Fu-Min Fang, Chao-Cheng Huang, Hsuan-Ying Huang, Han-Ku Chen, Chang-Han Chen, Chih-Yen Chien. (2011) Clinical and pathological determinants in tonsillar cancer. Head & Neck 33:12, 1703-1707
CrossRef45
Michael E. Montejo, Dennis C. Shrieve, Brandon G. Bentz, Jason P. Hunt, Luke O. Buchman, Neeraj Agarwal, Ying J. Hitchcock. (2011) IMRT With Simultaneous Integrated Boost and Concurrent Chemotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics 81:5, e845-e852
CrossRef46
James S Lewis Jr, Raja A Khan, Ramya P Masand, Rebecca D Chernock, Qin Zhang, Nasser Said Al-Naief, Susan Muller, Jonathan B McHugh, Manju L Prasad, Margaret Brandwein-Gensler, Bayardo Perez-Ordonez, Samir K El-Mofty. (2011) Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma - a prospective cohort and interobserver variability study*. Histopathologyno-no
CrossRef47
R. Granata, R. Miceli, E. Orlandi, F. Perrone, B. Cortelazzi, M. Franceschini, L. D. Locati, P. Bossi, C. Bergamini, A. Mirabile, L. Mariani, P. Olmi, G. Scaramellini, P. Potepan, P. Quattrone, K. K. Ang, L. Licitra. (2011) Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Annals of Oncology
CrossRef48
Robin J. Prestwich, Didem Çolpan Öksüz, Karen Dyker, Catherine Coyle, Mehmet Şen. (2011) Feasibility and Efficacy of Induction Docetaxel, Cisplatin, and 5-Fluorouracil Chemotherapy Combined With Cisplatin Concurrent Chemoradiotherapy for Nonmetastatic Stage IV Head-and-Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology*Biology*Physics 81:4, e237-e243
CrossRef49
Jason T. Rich, Jingxia Liu, Bruce H. Haughey. (2011) Swallowing function after transoral laser microsurgery (TLM) ± adjuvant therapy for advanced-stage oropharyngeal cancer. The Laryngoscope 121:11, 2381-2390
CrossRef50
Graham W. Warren, Susanne M. Arnold, Joseph P. Valentino, Thomas J. Gal, Andrew J. Hyland, Anurag K. Singh, Vivek M. Rangnekar, K. Michael Cummings, James R. Marshall, Mahesh R. Kudrimoti. (2011) Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiotherapy and Oncology
CrossRef51
Florian Clatot, Jean-Michel Picquenot, Olivier Choussy, Sophie Gouérant, Cristian Moldovan, Didier Schultheis, Marie Cornic, Arnaud François, Emmanuel Blot, Sophie Laberge-Le-Couteulx. (2011) Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncology 47:11, 1062-1068
CrossRef52
Justin A. Bishop, William H. Westra. (2011) Human Papillomavirus-Related Small Cell Carcinoma of the Oropharynx. The American Journal of Surgical Pathology 35:11, 1679-1684
CrossRef53
Sagar C. Patel, Trevor Hackman, David Neil Hayes, Bhishamjit S. Chera. (2011) De-intensification of treatment for human papilloma virus associated oropharyngeal squamous cell carcinoma: A discussion of current approaches. Practical Radiation Oncology
CrossRef54
Marc Hamoir, Alfio Ferlito, Sandra Schmitz, François-Xavier Hanin, Juliette Thariat, Birgit Weynand, Jean-Pascal Machiels, Vincent Grégoire, K. Thomas Robbins, Carl E. Silver, Primož Strojan, Alessandra Rinaldo, June Corry, Robert P. Takes. (2011) The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncology
CrossRef55
Myriam Loyo, Jonas T. Johnson, William H. Westra, Simion I. Chiosea, Christine G. Gourin. (2011) Management of the “Violated Neck” in the era of chemoradiation. The Laryngoscope 121:11, 2349-2358
CrossRef56
Fumihito Sato, Isao Oze, Daisuke Kawakita, Noriyuki Yamamoto, Hidemi Ito, Satoyo Hosono, Takeshi Suzuki, Takakazu Kawase, Hiroki Furue, Miki Watanabe, Shunzo Hatooka, Yasushi Yatabe, Yasuhisa Hasegawa, Masayuki Shinoda, Minoru Ueda, Kazuo Tajima, Hideo Tanaka, Keitaro Matsuo. (2011) Inverse association between toothbrushing and upper aerodigestive tract cancer risk in a Japanese population. Head & Neck 33:11, 1628-1637
CrossRef57
Yung-Sung Huang, Ching-Chieh Lee, Ting-Shou Chang, Hsu-Chueh Ho, Yu-Chieh Su, Shih-Kai Hung, Moon-Sing Lee, Pesus Chou, Yu-Han Chang, Ching-Chih Lee. (2011) Increased risk of stroke in young head and neck cancer patients treated with radiotherapy or chemotherapy. Oral Oncology 47:11, 1092-1097
CrossRef58
H. H. Sudhoff, H. P. Schwarze, D. Winder, L. Steinstraesser, Martin Görner, M. Stanley, P. K. C. Goon. (2011) Evidence for a causal association for HPV in head and neck cancers. European Archives of Oto-Rhino-Laryngology 268:11, 1541-1547
CrossRef59
Paramita Baruah, Michael Lee, Tunde Odutoye, Peter Williamson, Nicholas Hyde, Juan Carlos Kaski, Ingrid E. Dumitriu. (2011) Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology
CrossRef60
Gypsyamber D'Souza, Amanda Dempsey. (2011) The role of HPV in head and neck cancer and review of the HPV vaccine. Preventive Medicine 53, S5-S11
CrossRef61
Nicolas F Schlecht, Margaret Brandwein-Gensler, Gerard J Nuovo, Maomi Li, Anne Dunne, Nicole Kawachi, Richard V Smith, Robert D Burk, Michael B Prystowsky. (2011) A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Modern Pathology 24:10, 1295-1305
CrossRef62
Matthew Foote, Michael Veness, Dannie Zarate, Michael Poulsen. (2011) Merkel cell carcinoma: The prognostic implications of an occult primary in stage IIIB (nodal) disease. Journal of the American Academy of Dermatology
CrossRef63
Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Jae-Yong Kwak, Soo Teik Lee, Jong Hun Kim, Jung-Soo Kim, Ho Sung Park, Ik-Joo Chung, Hyun-Jeong Shim, Jun-Eul Hwang, Hyeong Rok Kim, Taek-Keun Nam, Moo-Rim Park, Hyeok Shim, Hyo Sook Park, Hee Sun Kim, Chang-Yeol Yim. (2011) The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. International Journal of Cancer 129:7, 1752-1760
CrossRef64
Nadine C. Olthof, Jos M.J.A.A. Straetmans, Robert Snoeck, Frans C.S. Ramaekers, Bernd Kremer, Ernst-Jan M. Speel. (2011) Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go?. Reviews in Medical Virologyn/a-n/a
CrossRef65
Danielle H Carpenter, Samir K El-Mofty, James S Lewis. (2011) Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. Modern Pathology 24:10, 1306-1312
CrossRef66
Gregory M. Chronowski, Adam S. Garden, William H. Morrison, Steven J. Frank, David L. Schwartz, Shalin J. Shah, Beth M. Beadle, G. Brandon Gunn, Michael E. Kupferman, Kian K. Ang, David I. Rosenthal. (2011) Unilateral Radiotherapy for the Treatment of Tonsil Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef67
Jay H. Lubin, Joshua Muscat, Mia M. Gaudet, Andrew F. Olshan, Maria Paula Curado, Luigino Dal Maso, Victor Wünsch-Filho, Erich M. Sturgis, Neonilia Szeszenia-Dabrowska, Xavier Castellsague, Zuo-Feng Zhang, Elaine Smith, Leticia Fernandez, Elena Matos, Silvia Franceschi, Eleonora Fabianova, Peter Rudnai, Mark P. Purdue, Dana Mates, Qingyi Wei, Rolando Herrero, Karl Kelsey, Hal Morgenstern, Oxana Shangina, Sergio Koifman, Jolanta Lissowska, Fabio Levi, Alexander W. Daudt, Jose Eluf Neto, Chu Chen, Philip Lazarus, Deborah M. Winn, Stephen M. Schwartz, Paolo Boffetta, Paul Brennan, Ana Menezes, Carlo La Vecchia, Michael McClean, Renato Talamini, Thangarajan Rajkumar, Richard B. Hayes, Mia Hashibe. (2011) An examination of male and female odds ratios by BMI, cigarette smoking, and alcohol consumption for cancers of the oral cavity, pharynx, and larynx in pooled data from 15 case–control studies. Cancer Causes & Control 22:9, 1217-1231
CrossRef68
Gerrit Spanier, Fabian Pohl, Thorsten Giese, Johannes K. Meier, Oliver Koelbl, Torsten E. Reichert. (2011) Fatal course of tonsillar squamous cell carcinoma associated with Fanconi anaemia: A mini review. Journal of Cranio-Maxillofacial Surgery
CrossRef69
Barbara Burtness. (2011) Commentary. The Cancer Journal 17:5, 273-275
CrossRef70
David I PRYOR, Benjamin SOLOMON, Sandro V PORCEDDU. (2011) The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. Asia-Pacific Journal of Clinical Oncology 7:3, 236-251
CrossRef71
John D. Hainsworth, David R. Spigel, F. Anthony Greco, Dianna L. Shipley, James Peyton, Mark Rubin, Michael Stipanov, Anthony Meluch. (2011) Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck. The Cancer Journal 17:5, 267-272
CrossRef72
László Tamás, Gabriella Szentkúti, Mónika Erős, Kornél Dános, Diána Brauswetter, Béla Szende, Ivett Zsákovics, Tibor Krenács. (2011) Differential Biomarker Expression in Head and Neck Cancer Correlates with Anatomical Localization. Pathology & Oncology Research 17:3, 721-727
CrossRef73
Maria J Worsham. (2011) Identifying the risk factors for late-stage head and neck cancer. Expert Review of Anticancer Therapy 11:9, 1321-1325
CrossRef74
X. Dufour, A. Beby-Defaux, G. Agius, J. Lacau St Guily. (2011) HPV and head and neck cancer. European Annals of Otorhinolaryngology, Head and Neck Diseases
CrossRef75
Marie Lundberg, Ilmo Leivo, Kauko Saarilahti, Antti A. Mäkitie, Petri S. Mattila. (2011) Increased incidence of oropharyngeal cancer and p16 expression. Acta Oto-laryngologica 131:9, 1008-1011
CrossRef76
C. Wittekindt, S. Wagner, J.P. Klußmann. (2011) Humane Papillomaviren bei Kopf-Hals-Karzinomen. HNO 59:9, 885-892
CrossRef77
A. Dietz, G. Wichmann. (2011) Translationale Forschung bei Kopf-Hals-Tumoren. HNO 59:9, 874-884
CrossRef78
Paolo Boscolo-Rizzo, Enrico Muzzi, Franco Trabalzini, Alessandro Gava, Marco Stellin, Maria Cristina Mosto. (2011) Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology 268:9, 1349-1355
CrossRef79
John Bryan Lott. (2011) Oncolytic viruses: a new paradigm for treatment of head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology
CrossRef80
N. Agrawal, M. J. Frederick, C. R. Pickering, C. Bettegowda, K. Chang, R. J. Li, C. Fakhry, T.-X. Xie, J. Zhang, J. Wang, N. Zhang, A. K. El-Naggar, S. A. Jasser, J. N. Weinstein, L. Trevino, J. A. Drummond, D. M. Muzny, Y. Wu, L. D. Wood, R. H. Hruban, W. H. Westra, W. M. Koch, J. A. Califano, R. A. Gibbs, D. Sidransky, B. Vogelstein, V. E. Velculescu, N. Papadopoulos, D. A. Wheeler, K. W. Kinzler, J. N. Myers. (2011) Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. Science 333:6046, 1154-1157
CrossRef81
Ana Aparicio, Robert B. Den, Karen E. Knudsen. (2011) Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nature Reviews Urology 8:10, 562-568
CrossRef82
P. Boscolo-Rizzo, A. Gava, C. Marchiori, V. Baggio, M. C. Da Mosto. (2011) Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy. Annals of Oncology 22:8, 1894-1901
CrossRef83
Cécile Ortholan, Karen Benezery, Olivier Dassonville, Gilles Poissonnet, Alexandre Bozec, Nicole Guiochet, Yazid Belkacemi. (2011) A specific approach for elderly patients with head and neck cancer. Anti-Cancer Drugs 22:7, 647-655
CrossRef84
Victor Lopes, Paul Murray, Hazel Williams, Ciaran Woodman, John Watkinson, Max Robinson. (2011) Squamous cell carcinoma of the oral cavity rarely harbours oncogenic human papillomavirus. Oral Oncology 47:8, 698-701
CrossRef85
Janki Mohan Babu, R. Prathibha, V.S. Jijith, Ramkumar Hariharan, M. Radhakrishna Pillai. (2011) A miR-centric view of head and neck cancers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1816:1, 67-72
CrossRef86
Amanda Psyrri, Eleni Boutati, Sofia Karageorgopoulou. (2011) Human papillomavirus in head and neck cancers. Anti-Cancer Drugs 22:7, 586-590
CrossRef87
Apostolos Menegakis, Wolfgang Eicheler, Ala Yaromina, Howard D. Thames, Mechthild Krause, Michael Baumann. (2011) Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiotherapy and Oncology 100:1, 137-144
CrossRef88
Agnès Beby-Defaux, Xavier Dufour, Gérard Agius. (2011) Infections à papillomavirus humains (HPV) des voies aéro-digestives supérieures (VADS). Revue Francophone des Laboratoires 2011:434, 65-75
CrossRef89
Richard Jordan, Maura Gillison, Annemieke van Zante. (2011) Oropharyngeal Carcinoma. Pathology Case Reviews 16:4, 173-175
CrossRef90
Pernille Lassen, Jesper G. Eriksen, Annelise Krogdahl, Marianne Hamilton Therkildsen, Benedicte P. Ulhøi, Marie Overgaard, Lena Specht, Elo Andersen, Jørgen Johansen, Lisbeth J. Andersen, Cai Grau, Jens Overgaard. (2011) The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiotherapy and Oncology 100:1, 49-55
CrossRef91
Vincent Gregoire, Marc Hamoir, Changhu Chen, Madeleine Kane, Andrzej Kawecki, Pramod K. Julka, Hung-Ming Wang, Srihari Prasad, Anil K. D’Cruz, Ljiljana Radosevic-Jelic, Rejnish R. Kumar, Stanislaw Korzeniowski, Jacek Fijuth, Jean-Pascal Machiels, Mark V. Sellers, Ilian Tchakov, David Raben. (2011) Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Radiotherapy and Oncology 100:1, 62-69
CrossRef92
Andreas H. Brunner, Christoph Grimm, Stephan Polterauer, Lukas Hefler, Josefine Stani, Georg Heinze, Reinhard Horvat. (2011) The Prognostic Role of Human Papillomavirus in Patients With Vaginal Cancer. International Journal of Gynecological Cancer 21:5, 923-929
CrossRef93
Abrahim Al-Mamgani, Lisa Tans, David N. Teguh, Peter van Rooij, Ellen M. Zwijnenburg, Peter C. Levendag. (2011) Stereotactic Body Radiotherapy: A Promising Treatment Option for the Boost of Oropharyngeal Cancers Not Suitable for Brachytherapy: A Single-Institutional Experience. International Journal of Radiation Oncology*Biology*Physics
CrossRef94
K S Anderson, J Wong, G D'Souza, A B Riemer, J Lorch, R Haddad, S I Pai, J Longtine, M McClean, J LaBaer, K T Kelsey, M Posner. (2011) Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. British Journal of Cancer 104:12, 1896-1905
CrossRef95
Ramya P. Masand, Samir K. El-Mofty, Xiao-Jun Ma, Yuling Luo, John J. Flanagan, James S. Lewis. (2011) Adenosquamous Carcinoma of the Head and Neck: Relationship to Human Papillomavirus and Review of the Literature. Head and Neck Pathology 5:2, 108-116
CrossRef96
S. Tuttleton Arron, L. Jennings, I. Nindl, F. Rosl, J.N. Bouwes Bavinck, D. Seçkin, M. Trakatelli, G.M. Murphy, . (2011) Viral oncogenesis and its role in nonmelanoma skin cancer. British Journal of Dermatology 164:6, 1201-1213
CrossRef97
G. Lescaille, V. Descroix, J. Azérad. (2011) Papillomavirus et cancers des VADS. Revue de Stomatologie et de Chirurgie Maxillo-faciale 112:3, 160-163
CrossRef98
Benjamin H. Lok, Jeremy Setton, Nicola Caria, Jonathan Romanyshyn, Suzanne L. Wolden, Michael J. Zelefsky, Jeffery Park, Nicholas Rowan, Eric J. Sherman, Matthew G. Fury, Alan Ho, David G. Pfister, Richard J. Wong, Jatin P. Shah, Dennis H. Kraus, Zhigang Zhang, Karen D. Schupak, Daphna Y. Gelblum, Shyam D. Rao, Nancy Y. Lee. (2011) Intensity-Modulated Radiation Therapy in Oropharyngeal Carcinoma: Effect of Tumor Volume on Clinical Outcomes. International Journal of Radiation Oncology*Biology*Physics
CrossRef99
Shao Hui Huang, Tara Rosewall. (2011) Human Papillomavirus-related Oropharyngeal Carcinoma: Current Understanding and Enduring Uncertainties. Journal of Medical Imaging and Radiation Sciences 42:2, 86-94
CrossRef100
Peter Friedland, Anitha Thomas, Anupam Naran, Benhur Amanuel, Fabienne Grieu-Iacopetta, Amerigo Carrello, Gerald Harnett, Christine Meyer, Michael Phillips. (2011) Human papillomavirus and gene mutations in head and neck squamous carcinomas. ANZ Journal of Surgeryno-no
CrossRef101
Rebecca Shanesmith, Richard A. Allen, William E. Moore, Douglas W. Kingma, Samuel K. Caughron, Elizabeth M. Gillies, Samuel T. Dunn. (2011) Comparison of 2 line blot assays for defining HPV genotypes in oral and oropharyngeal squamous cell carcinomas. Diagnostic Microbiology and Infectious Disease 70:2, 240-245
CrossRef102
Andreas Dietz, Gunnar Wichmann. (2011) Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences. The EPMA Journal 2:2, 241-249
CrossRef103
Mohan Suntharalingam, Young Kwok, Olga Goloubeva, Arti Parekh, Rodney Taylor, Jeffrey Wolf, Ann Zimrin, Scott Strome, Robert Ord, Kevin J Cullen. (2011) Phase II Study Evaluating the Addition of Cetuximab to the Concurrent Delivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics
CrossRef104
Miroslaw Snietura, Wojciech Piglowski, Magdalena Jaworska, Anna Mucha-Malecka, Grzegorz Wozniak, Dariusz Lange, Rafal Suwinski. (2011) Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer. European Archives of Oto-Rhino-Laryngology 268:5, 721-726
CrossRef105
M. R. Posner, J. H. Lorch, O. Goloubeva, M. Tan, L. M. Schumaker, N. J. Sarlis, R. I. Haddad, K. J. Cullen. (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Annals of Oncology 22:5, 1071-1077
CrossRef106
A. Psyrri, E. Cohen. (2011) Oropharyngeal cancer: clinical implications of the HPV connection. Annals of Oncology 22:5, 997-999
CrossRef107
Mariana BA Ferreira, Jonas A De Souza, Ezra EW Cohen. (2011) Role of molecular markers in the management of head and neck cancers. Current Opinion in Oncology 23:3, 259-264
CrossRef108
David M. Brizel. (2011) Head and Neck Cancer as a Model for Advances in Imaging Prognosis, Early Assessment, and Posttherapy Evaluation. The Cancer Journal 17:3, 159-165
CrossRef109
Silke Tribius, Anna S. Ihloff, Thorsten Rieckmann, Cordula Petersen, Markus Hoffmann. (2011) Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know. Cancer Letters 304:2, 71-79
CrossRef110
Nicole G Chau, Bonnie S Glisson. (2011) Emerging therapies for head and neck cancer: review of the Phase II and III trials. Clinical Investigation 1:5, 669-687
CrossRef111
Wei-Chi Tseng, Shyue-Yih Chang, Pen-Yuan Chu, Shyh-Kuan Tai, Yi-Feng Wang, An-Suey Shiao, Tung-Lung Tsai. (2011) Management of base of tongue squamous cell carcinoma: Experience with 85 patients in Taipei Veterans General Hospital. Journal of the Chinese Medical Association 74:5, 220-225
CrossRef112
Ian H. Frazer, Graham R. Leggatt, Stephen R. Mattarollo. (2011) Prevention and Treatment of Papillomavirus-Related Cancers Through Immunization. Annual Review of Immunology 29:1, 111-138
CrossRef113
A. Argiris, M. V. Karamouzis. (2011) Empowering induction therapy for locally advanced head and neck cancer. Annals of Oncology 22:4, 773-781
CrossRef114
Karine Ligier, Aurélien Belot, Guy Launoy, Michel Velten, Nadine Bossard, Jean Iwaz, Christian Adrien Righini, Patricia Delafosse, Anne-Valérie Guizard. (2011) Descriptive epidemiology of upper aerodigestive tract cancers in France: Incidence over 1980–2005 and projection to 2010. Oral Oncology 47:4, 302-307
CrossRef115
S Syrjänen, G Lodi, I von Bültzingslöwen, A Aliko, P Arduino, G Campisi, S Challacombe, G Ficarra, C Flaitz, HM Zhou, H Maeda, C Miller, M Jontell. (2011) Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Diseases 17, 58-72
CrossRef116
Hosam A Kader, Darin A Wick, John R Webb. (2011) Research Highlights: Do conventional treatments for HPV-positive head and neck cancers elicit immunotherapeutic type responses?. Immunotherapy 3:4, 469-473
CrossRef117
D. Rossi, V. Spina, C. Deambrogi, S. Rasi, L. Laurenti, K. Stamatopoulos, L. Arcaini, M. Lucioni, G. B. Rocque, Z. Y. Xu-Monette, C. Visco, J. Chang, E. Chigrinova, F. Forconi, R. Marasca, C. Besson, T. Papadaki, M. Paulli, L. M. Larocca, S. A. Pileri, V. Gattei, F. Bertoni, R. Foa, K. H. Young, G. Gaidano. (2011) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117:12, 3391-3401
CrossRef118
Abdul Ahmed, Luke Cascarini, Ann Sandison, Peter Clarke. (2011) Survey of the use of tests for human papilloma virus and epidermal growth factor receptor for squamous cell carcinoma of the head and neck in UK head and neck multidisciplinary teams. British Journal of Oral and Maxillofacial Surgery
CrossRef119
Frank C. Detterbeck. (2011) Maintaining Aim at a Moving Target. Journal of Thoracic Oncology 6:3, 417-422
CrossRef120
Bruce E. Brockstein, Everett E. Vokes. (2011) Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nature Reviews Clinical Oncology 8:2, 72-74
CrossRef121
Jochen H Lorch, Olga Goloubeva, Robert I Haddad, Kevin Cullen, Nicholas Sarlis, Roy Tishler, Ming Tan, John Fasciano, Daniel E Sammartino, Marshall R Posner. (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. The Lancet Oncology 12:2, 153-159
CrossRef122
Yin Wu, Marshall R. Posner, Lisa M. Schumaker, Nikolaos Nikitakis, Olga Goloubeva, Ming Tan, Changwan Lu, Sana Iqbal, Jochen Lorch, Nicholas J. Sarlis, Robert I. Haddad, Kevin J. Cullen. (2011) Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer. Cancern/a-n/a
CrossRef123
Akira Kubota. (2011) Concurrent chemoradiotherapy for unresectable head and neck cancers. Toukeibu Gan 37:4, 464-469
CrossRef124
Richard L. Cantley, Eleonora Gabrielli, Francesco Montebelli, David Cimbaluk, Paolo Gattuso, Guy Petruzzelli. (2011) Ancillary Studies in Determining Human Papillomavirus Status of Squamous Cell Carcinoma of the Oropharynx: A Review. Pathology Research International 2011, 1-7
CrossRef125
Primož Strojan, Alfio Ferlito, Johannes A. Langendijk, June Corry, Julia A. Woolgar, Alessandra Rinaldo, Carl E. Silver, Vinidh Paleri, Johannes J. Fagan, Phillip K. Pellitteri, Missak Haigentz, Carlos Suárez, K. Thomas Robbins, Juan P. Rodrigo, Kerry D. Olsen, Michael L. Hinni, Jochen A. Werner, Vanni Mondin, Luiz P. Kowalski, Kenneth O. Devaney, Remco de Bree, Robert P. Takes, Gregory T. Wolf, Ashok R. Shaha, Eric M. Genden, Leon Barnes. (2011) Contemporary management of lymph node metastases from an unknown primary to the neck: II. A review of therapeutic options. Head & Neckn/a-n/a
CrossRef126
Abul Kalam Azad, Isabelle Bairati, Elodie Samson, Dangxiao Cheng, Lu Cheng, Maryam Mirshams, Sevtap Savas, John Waldron, Changshu Wang, David Goldstein, Wei Xu, Francois Meyer, Geoffrey Liu. (2011) Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. Cancern/a-n/a
CrossRef127
Linda Marklund, Lalle Hammarstedt. (2011) Impact of HPV in Oropharyngeal Cancer. Journal of Oncology 2011, 1-6
CrossRef128
Shao Hui Huang, Brian O'Sullivan, Ilan Weinreb, Bayardo Perez-Ordonez, Jonathan Irish, John Waldron, Patrick Gullane, Ralph Gilbert, Dale Brown, Bernard Cummings, John Kim, Jeremy Freeman, Ian Witterick, David Goldstein. (2011) Patterns of failure and histopathologic outcome predictors following definitive radiotherapy and planned neck dissection with residual disease. Head & Neckn/a-n/a
CrossRef129
Nabil F. Saba, Michael Goodman, Kevin Ward, Chris Flowers, Suresh Ramalingam, Taofeek Owonikoko, Amy Chen, William Grist, Trad Wadsworth, Jonathan J. Beitler, Fadlo R. Khuri, Dong M. Shin. (2011) Gender and Ethnic Disparities in Incidence and Survival of Squamous Cell Carcinoma of the Oral Tongue, Base of Tongue, and Tonsils: A Surveillance, Epidemiology and End Results Program-Based Analysis. Oncology 81:1, 12-20
CrossRef130
Didem C Oksuz, Robin J Prestwich, Brendan Carey, Stuart Wilson, Mustafa S Senocak, Ananya Choudhury, Karen Dyker, Catherine Coyle, Mehmet Sen. (2011) Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. Radiation Oncology 6:1, 54
CrossRef131
Adel K. El-Naggar, William H. Westra. (2011) p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency. Head & Neckn/a-n/a
CrossRef132
Justin A. Bishop, Zahra Maleki, Alexandra Valsamakis, Takenori Ogawa, Xiaofei Chang, Sara I. Pai, William H. Westra. (2011) Application of the Hybrid Capture 2 assay to squamous cell carcinomas of the head and neck. Cancer Cytopathologyn/a-n/a
CrossRef133
Bibianna Purgina, Liron Pantanowitz, Raja R. Seethala. (2011) A Review of Carcinomas Arising in the Head and Neck Region in HIV-Positive Patients. Pathology Research International 2011, 1-12
CrossRef134
Alice L. Tang, Samantha J. Hauff, John H. Owen, Martin P. Graham, Michael J. Czerwinski, Jung Je Park, Heather Walline, Silvana Papagerakis, Jay Stoerker, Jonathan B. McHugh, Douglas B. Chepeha, Carol R. Bradford, Thomas E. Carey, Mark E. Prince. (2011) UM-SCC-104: A New human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head & Neckn/a-n/a
CrossRef135
C. René Leemans, Boudewijn J. M. Braakhuis, Ruud H. Brakenhoff. (2011) The molecular biology of head and neck cancer. Nature Reviews Cancer 11:1, 9-22
CrossRef136
Per Attner, Anders Näsman, Juan Du, Lalle Hammarstedt, Torbjörn Ramqvist, Johan Lindholm, Eva Munck-Wikland, Tina Dalianis, Linda Marklund. (2011) Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. International Journal of Cancern/a-n/a
CrossRef137
H.S. van Monsjou, M.L.F. van Velthuysen, M.W.M. van den Brekel, E.S. Jordanova, C.J.M. Melief, A.J.M. Balm. (2011) Human papillomavirus status in young patients with head and neck squamous cell carcinoma. International Journal of Cancern/a-n/a
CrossRef138
Takuji Tanaka, Rikako Ishigamori. (2011) Understanding Carcinogenesis for Fighting Oral Cancer. Journal of Oncology 2011, 1-10
CrossRef139
Parul Sinha, James S. Lewis, Jay F. Piccirillo, Dorina Kallogjeri, Bruce H. Haughey. (2011) Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancern/a-n/a
CrossRef140
Stephanie A. Michal, David J. Adelstein, Lisa A. Rybicki, Cristina P. Rodriguez, Jerrold P. Saxton, Benjamin G. Wood, Joseph Scharpf, Denise I. Ives. (2011) Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head & Neckn/a-n/a
CrossRef141
Takuji Tanaka, Mayu Tanaka, Takahiro Tanaka. (2011) Oral Carcinogenesis and Oral Cancer Chemoprevention: A Review. Pathology Research International 2011, 1-10
CrossRef142
Edward M. Mannina, Sunanda M. Pejavar, Christine M. Glastonbury, Annemieke van Zante, Steven J. Wang, Sue S. Yom. (2011) Diagnosis of Bilateral Tonsil Cancers via Staging PET/CT: Case Report and Review. International Journal of Otolaryngology 2011, 1-5
CrossRef143
Samir S. Khariwala, Dorothy Hatsukami, Stephen S. Hecht, Jeffrey N. Myers. (2011) Tobacco carcinogen metabolites and DNA adducts as biomarkers in Head and Neck cancer: Potential screening tools and prognostic indicators. Head & Neckn/a-n/a
CrossRef144
Bertrand Baujat, Jean Bourhis, Pierre Blanchard, Jens Overgaard, Kian K Ang, Michelle Saunders, Aurélie Le Maître, Jacques Bernier, Jean Claude Horiot, Emilie Maillard, Thomas F Pajak, Michael G Poulsen, Abderrahmane Bourredjem, Brian O'Sullivan, Werner Dobrowsky, Hliniak Andrzej, Krzystof Skladowski, John H Hay, Luiz HJ Pinto, Karen K Fu, Carlo Fallai, Richard Sylvester, Jean Pierre Pignon, , Jean Pierre Pignon. 2010. Hyperfractionated or accelerated radiotherapy for head and neck cancer. .
CrossRef145
T Lampejo, D Kavanagh, J Clark, R Goldin, M Osborn, P Ziprin, S Cleator. (2010) Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. British Journal of Cancer 103:12, 1858-1869
CrossRef146
A M Hong, T A Dobbins, C S Lee, D Jones, G B Harnett, B K Armstrong, J R Clark, C G Milross, J Kim, C J O'Brien, B R Rose. (2010) Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. British Journal of Cancer 103:10, 1510-1517
CrossRef147
Hester S. van Monsjou, Alfons J.M. Balm, Michiel M. van den Brekel, Volkert B. Wreesmann. (2010) Oropharyngeal squamous cell carcinoma: A unique disease on the rise?. Oral Oncology 46:11, 780-785
CrossRef148
Ophélie Marais. (2010) Cancer oropharyngé HPV+ de mauvais pronostic. Actualités Pharmaceutiques Hospitalières 6:24, 5
CrossRef149
Anthony Prince, Julio Aguirre-Ghizo, Eric Genden, Marshall Posner, Andrew Sikora. (2010) Head and Neck Squamous Cell Carcinoma: New Translational Therapies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:6, 684-699
CrossRef150
(2010) Human Papillomavirus and Oropharyngeal Cancer Survival. New England Journal of Medicine 363:16, 1576-1576
Full Text151
J. A. Langendijk, A. Psyrri. (2010) The prognostic significance of p16 overexpression in oropharyngeal squamous cell carcinoma: implications for treatment strategies and future clinical studies. Annals of Oncology 21:10, 1931-1934
CrossRef152
Lisa Richards. (2010) Epidemiology: Human papillomavirus—a powerful predictor of survival in patients with oropharyngeal cancer. Nature Reviews Clinical Oncology 7:9, 481-481
CrossRef153
Lowy, Douglas R., Munger, Karl, . (2010) Prognostic Implications of HPV in Oropharyngeal Cancer. New England Journal of Medicine 363:1, 82-84
Full Text
- Letters
